Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

BioAge Labs, Inc.

35 indications, side-by-side phase, drug & LoA

$18.04

+1.59 (+9.67%)

D 23Pipeline Score Richly Valued Biotech · Commercial
Market Cap
738.36 M
EPS
-2.41
P/E Ratio
-
Value Trade
4.19 M
SEC Financials
Q1 2026

  • Dilution Risk

    15%

  • Revenue

    2.77 M

  • R&D Expenses

    20.41 M

  • Operating CF

    -24.05 M

  • Total Assets

    397.65 M

  • Total Liabilities

    18.53 M

  • Equity

    379.12 M

  • D/E Ratio

    12,345

-8.59 %
Week
-16.36 %
1 Month
-17.49 %
3 Month
93.36 %
6 Month
-26.18 %
5 Year
-26.18 %
All Time
Cash Data
Healthy

  • Cash Position

    383.19 M

  • Monthly Burn

    8.02 M

  • Runway

    46.7 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 8, 2026
Overview
Volume
436.92 K
52 Week Range
3.79 - 24
% held by Insiders
28.8 %
% held by Institutions
58.92 %
Enterprise Value
359.20 M
Total Shares
35.86 M
Short %
5.65 %
Float Shares
18.50 M
Company Description
HQ: 5885 HOLLIS STREET, EMERYVILLE...
Employees:62
https://www.bioagelabs.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Pre-clinical data readout example
BGE-102 Clinical data presentation (conference)
Pre-clinical
—
-
-
BGE-102 Clinical data presentation (conference)
Pre-clinical
—
-
-
BGE-102 Clinical data presentation (conference)
Pre-clinical
—
-
-
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D23
Pipeline Score
$15M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 21%
Micro Cap
(rank 716 of 905)
Percentile Rank
BioAge Labs, Inc. faces pipeline headwinds (23/100), with $73M risk-adjusted pipeline value, led by Azelaprag in Healthy Volunteer Study (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Azelaprag
Small molecule		Healthy Volunteer StudyPhase 1NCT0614188915% $73M COMPLETED 16 - -Feb 2, 2024 -Feb 23, 2024
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
apelin receptor agonist
diabetic obesity,heart failure with preserved ejection fraction
Preclinical
2025-06-23
apelin receptor agonist
diabetic obesity,heart failure with preserved ejection fraction
Preclinical
2025-06-23
apelin receptor agonist
diabetic obesity,heart failure with preserved ejection fraction
Preclinical
2025-06-23
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in BIOA
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
BIOA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BIOA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BIOA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
BIOA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
BIOA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest BioAge Labs, Inc. (BIOA) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How BIOA ranks across every disease it competes in
No competitive intelligence available for BIOA.